Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.63 |
| ▸ | SYK | P43405 | 5/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14026161 | 0.84 | CNR2 (0.58) | CNR2SYKCDC7MAOBGRM5 | |
| SCHEMBL4886226 | 0.83 | CNR2 (0.61) | CNR2SYKGRM5CYP1A2CYP2C9 | |
| SCHEMBL14026150 | 0.83 | CNR2 (0.55) | CNR2SYKCDC7MAOBGRM5 | |
| SCHEMBL14045929 | 0.83 | SYK (0.57) | CNR2SYKCDC7MAOBGRM5 | |
| SCHEMBL541880 | 0.82 | CNR2 (0.62) | CNR2SYKMAOBGRM5CYP1A2 | |
| SCHEMBL4889009 | 0.82 | CNR2 (0.54) | CNR2SYKCDC7MAOBGRM5 | |
| SCHEMBL3378844 | 0.81 | CNR2 (0.74) | CNR2SYKCDC7ZAP70CYP1A2 | |
| SCHEMBL4897341 | 0.81 | CDK1 (0.51) | CNR2SYKCDC7MAOBGRM5 | |
| Formic Acid SCHEMBL4895900 | 0.81 | CNR2 (0.57) | CNR2SYKCDC7MAOBGRM5 | |
| Formic Acid SCHEMBL4894255 | 0.81 | CNR2 (0.55) | CNR2SYKCDC7MAOBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1718620-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080350-A1 | PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885SYK 2878/4885CDC7 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.